您当前所在的位置:首页 > 产品中心 > 产品详细信息
57-27-2 分子结构
点击图片或这里关闭

(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraene-10,14-diol

ChemBase编号:180
分子式:C17H19NO3
平均质量:285.33766
单一同位素质量:285.13649347
SMILES和InChIs

SMILES:
O1[C@@H]2[C@]34[C@H]([C@H](N(CC3)C)Cc3c4c1c(O)cc3)C=C[C@@H]2O
Canonical SMILES:
O[C@H]1C=C[C@@H]2[C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)C)ccc1O
InChI:
InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
InChIKey:
BQJCRHHNABKAKU-KBQPJGBKSA-N

引用这个纪录

CBID:180 http://www.chembase.cn/molecule-180.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraene-10,14-diol
(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
IUPAC传统名
morphine
morph
商标名
M-Eslon
M.O.S
MS/L
MS/S
MSIR
Meconium
Morfina
Morphia
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphinism
Morphitec
Morphium
Moscontin
Ms Contin
Nepenthe
OMS Concentrate
Oramorph SR
Ospalivina
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
Statex
Statex Drops
l-Morphine
Apokyn
Astramorph PF
Avinza
Depodur
Dulcontin
Duramorph PF
Duromorph
Epimorph
Kadian
Mscontin, Oramorph
别名
吗啡 溶液
Morphine solution
(-)-Heroin hydrochloride
(-)-Morphine
D-(-)-Morphine
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Heroin hydrochloride
Heroine hydrochloride
Morphine Sulfate
Morphinum
O,O'-Diacetylmorphine hydrochloride
Morphin
Morphina
morphine
Morphine
CAS号
57-27-2
EC号
200-659-6
MDL号
MFCD00153032
PubChem SID
46505161
160963643
PubChem CID
5288826
CHEBI ID
17303
ATC码
N02AA01
CHEMBL
70
Chemspider ID
4450907
DrugBank ID
DB00295
IUPHAR配体索引
1627
KEGG ID
D08233
美国药典/FDA物质标识码
76I7G6D29C
维基百科标题
Morphine

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID 价格
Sigma Aldrich
610062 external link 加入购物车 请登录

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 10.2556095  质子受体
质子供体 LogD (pH = 5.5) -2.0906866 
LogD (pH = 7.4) -0.60061675  Log P 0.8952108 
摩尔折射率 80.1224 cm3 极化性 30.698988 Å3
极化表面积 52.93 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P 0.99  LOG S -1.45 
溶解度 1.02e+01 g/l 

分子性质

分子性质

理化性质 安全信息 药理学性质 产品相关信息 生物活性(PubChem)
溶解度
149 mg/L (60 mg/mL for sulfate salt) expand 查看数据来源
HCl & sulf.: 60 mg/mL (20°C) expand 查看数据来源
闪点
11 °C expand 查看数据来源
51.8 °F expand 查看数据来源
疏水性(logP)
0.8 expand 查看数据来源
欧盟危险性物质标志
易燃性(Flammable) 易燃性(Flammable) (F) expand 查看数据来源
有毒(Toxic) 有毒(Toxic) (T) expand 查看数据来源
联合国危险货物编号
1230 expand 查看数据来源
MSDS下载
下载链接 expand 查看数据来源
德国WGK号
1 expand 查看数据来源
联合国危险货物等级
3 expand 查看数据来源
联合国危险货物包装类别(PG)
2 expand 查看数据来源
危险公开号
11-23/24/25-39/23/24/25 expand 查看数据来源
安全公开号
7-16-36/37-45 expand 查看数据来源
GHS危险品标识
GHS02 expand 查看数据来源
GHS06 expand 查看数据来源
GHS08 expand 查看数据来源
GHS警示词
Danger expand 查看数据来源
GHS危险声明
H225-H301-H311-H331-H370 expand 查看数据来源
GHS警示性声明
P210-P260-P280-P301 + P310-P311 expand 查看数据来源
个人保护装置
Eyeshields, Faceshields, full-face respirator (US), Gloves, multi-purpose combination respirator cartridge (US), type ABEK (EN14387) respirator filter expand 查看数据来源
RID/ADR
UN 1230 3/PG 2 expand 查看数据来源
毒品管制信息
kontrollierte Droge in Deutschlandregulated under CDSA - not available from Sigma-Aldrich Canada expand 查看数据来源
保存温度
-20°C expand 查看数据来源
给药途径
Inhalation (smoking), insufflation (snorting), oral, rectal, subcutaneous (S.C), intramuscular (I.M), intravenous (I.V), and intrathecal (I.T) expand 查看数据来源
生物利用度
20-40% (oral), 36-71% (rectally), 100% (IV/IM) expand 查看数据来源
依赖倾向
High expand 查看数据来源
排泄
Renal 90%, biliary 10% expand 查看数据来源
半衰期
2–3 h expand 查看数据来源
代谢
Hepatic 90% expand 查看数据来源
蛋白结合率
30–40% expand 查看数据来源
法定药品分级
S8 (Australia) expand 查看数据来源
Schedule I (Canada) expand 查看数据来源
Schedule II (US) expand 查看数据来源
妊娠期药物分类
C (Australia) expand 查看数据来源
C (US) expand 查看数据来源
浓度
1 mg/mL in methanol expand 查看数据来源
级别
drug standard expand 查看数据来源
Empirical Formula (Hill Notation)
C17H19NO3 expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank Wikipedia Wikipedia Sigma Aldrich Sigma Aldrich
DrugBank -  DB00295 external link
Item Information
Drug Groups approved; investigational
Description The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. [PubChem]
Indication For the relief and treatment of severe pain.
Pharmacology Morphine is a narcotic pain management agent indicated for the relief of pain in patients who require opioid analgesics for more than a few days. Morphine interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. In clinical settings, morphine exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Its primary actions of therapeutic value are analgesia and sedation. Morphine appears to increase the patient's tolerance for pain and to decrease discomfort, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Opioids also produce respiratory depression by direct action on brain stem respiratory centers.
Toxicity LD50 = 461 mg/kg (rat, oral), 600 mg/kg (mouse, oral). Human lethal dose by ingestion is 120-250 mg of morphine sulfate. Symptoms of overdose include cold, clammy skin, flaccid muscles, fluid in the lungs, lowered blood pressure, "pinpoint" or dilated pupils, sleepiness leading to stupor and coma, slowed breathing, and slow pulse rate.
Affected Organisms
Humans and other mammals
Biotransformation Primarily hepatic (90%), converted to dihydromorphinone and normorphine. Also converted to morphine-3-glucuronide (M3G) and morphine-6-glucuronide. Virtually all morphine is converted to glucuronide metabolites; only a small fraction (less than 5%) of absorbed morphine is demethylated.
Absorption Bioavailability is approximately 30%.
Half Life 2-4 hours
Protein Binding 30-40%
Elimination A small amount of glucuronide conjugates are excreted in bile, with minor enterohepatic recycling. Seven to 10% of administered morphine sulfate is excreted in the feces.
Distribution * 1 to 6 L/kg
Clearance * 20 – 30 mL/min/kg [Adult]
* 1852 +/- 116 mL/min [Chinese]
* 1495 +/- 80 mL/min [Caucasian]
References
Kilpatrick GJ, Smith TW: Morphine-6-glucuronide: actions and mechanisms. Med Res Rev. 2005 Sep;25(5):521-44. [Pubmed]
Loguinov AV, Anderson LM, Crosby GJ, Yukhananov RY: Gene expression following acute morphine administration. Physiol Genomics. 2001 Aug 28;6(3):169-81. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com
Sigma Aldrich -  610062 external link
Other Notes
Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. 610062.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Kilpatrick GJ, Smith TW: Morphine-6-glucuronide: actions and mechanisms. Med Res Rev. 2005 Sep;25(5):521-44. Pubmed
  • Loguinov AV, Anderson LM, Crosby GJ, Yukhananov RY: Gene expression following acute morphine administration. Physiol Genomics. 2001 Aug 28;6(3):169-81. Pubmed
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle